Endomag

Endomag Announces FDA Approval of Magtrace for All Breast Cancer Staging Procedures

Retrieved on: 
Wednesday, December 7, 2022
Sentinel, Conference, Breast cancer, Woman, Physician, Surgeon, Mammotome, UCSF, Breast, Neoplasm, FDA, Anesthesia, Hospital, News, Cancer, TBCC, Lymph, Heart, Pain, DCIS, MD, Anaphylaxis, Lymph node, Nuclear medicine, Patient, Medical imaging, Birth control, Endomag

Magtrace is the first tracer specifically designed to optimize the breast cancer staging procedure, Sentinel Lymph Node Biopsy.

Key Points: 
  • Magtrace is the first tracer specifically designed to optimize the breast cancer staging procedure, Sentinel Lymph Node Biopsy.
  • Since then, additional data submitted to the FDA has validated its use for all breast cancer patients.
  • - Michael Alvarado, MD, Professor of Surgery at UCSF
    "This much-anticipated approval allows any surgeon, regardless of hospital setting, to offer their patients the best standard of treatment in breast cancer staging.
  • To date, the company has helped over 300,000 women around the world access more precise and less invasive breast cancer care.

Endomag: New Procedure Spares Women With Breast Cancer From Unnecessary Surgical Complication

Retrieved on: 
Wednesday, December 15, 2021
Oncology, Health, Consumer, Surgery, Women, Biotechnology, Sentinel, Hospital, Hand, LE, Disease, Pain, Swelling, Physician, Radiation, Kakuda, Diagnosis, Learning, Lymph, Incidence, American Journal, Woman, American Journal of Roentgenology, Breast cancer, Cancer, Lymph node, Tail of Spence, Strathcona County, Monroe Dunaway Anderson, Sensation, American College, Motion, Veni, vidi, vici, Trastuzumab, CEO, RN, Therapy, Lymphedema, Quality of life, TAD, MD Anderson Cancer Center, Infection, Lymphatic system, Surgeon, Multimedia, MD, Targeted intra-operative radiotherapy, Treatment, Technology, Heart, Axilla, Dentistry, Cryptocurrency, Medical imaging, Pharmaceutical industry, Silviculture, Endomag, Patient

A novel procedure could now spare breast cancer patients an invasive surgical procedure on their lymphatic system.

Key Points: 
  • A novel procedure could now spare breast cancer patients an invasive surgical procedure on their lymphatic system.
  • Women who win their battle against breast cancer routinely state that lymphedema can be worse than their cancer.
  • This pioneering surgery exemplifies the importance of new technologies such as Magseed in moving breast cancer treatment forward.
  • Prospective Trial of Magnetic Seed Localization of Clipped Nodes after Neoadjuvant Chemotherapy in Node Positive Breast Cancer.

MedStar Montgomery Medical Center Introduces Magseed Technology to Montgomery County, Improving the Standard of Cancer Care

Retrieved on: 
Thursday, October 21, 2021
Woman, Breast cancer, Technology, University, Hospital, Obstetrics, Cancer, Elective surgery, UCL, Surgeon, Neoplasm, Patient, Risk, MedStar Health, Magnetism, University College London, Breast, Oncology, Heart, Endomag, Physician, Medical imaging, Dentistry, Pharmaceutical industry, Birth control

OLNEY, Md., Oct. 21, 2021 /PRNewswire-PRWeb/ -- MedStar Montgomery Medical Center recently introduced an innovative cancer technology, the Magseed marker, to improve outcomes and the standard of cancer care in Montgomery County.

Key Points: 
  • OLNEY, Md., Oct. 21, 2021 /PRNewswire-PRWeb/ -- MedStar Montgomery Medical Center recently introduced an innovative cancer technology, the Magseed marker, to improve outcomes and the standard of cancer care in Montgomery County.
  • As the first hospital in the region to utilize the Magseed marker, MedStar Montgomery serves as an innovative local leader in breast health.
  • MedStar Montgomery Medical Center is a not-for-profit, acute care community hospital serving Montgomery County, Maryland.
  • For 100 years, MedStar Montgomery has served as a medical care provider and community health resource offering high-quality, personalized care.

Endomag: New Technique Renders Underarm Surgery Unnecessary for 80% of Women With Early Breast Cancer, Reducing Risk of Lymphedema

Retrieved on: 
Wednesday, September 8, 2021
Health, Surgery, Oncology, Medical Devices

A common treatment for DCIS is a mastectomy, where the patient will undergo surgery to remove the entire breast.

Key Points: 
  • A common treatment for DCIS is a mastectomy, where the patient will undergo surgery to remove the entire breast.
  • Every year over 50,000 American women with the earliest form of breast cancer receive this node surgery.3 Yet, 70-80% of women diagnosed with DCIS do not have invasive cancer,3,4 rendering this additional surgery unnecessary.
  • By preventing surgery, the new delayed sentinel lymph node biopsy spares womens lymph nodes and leaves the lymphatic system undamaged, reducing the risk of life-altering complications connected with lymph node surgery.
  • SENTINOT: Utilization of a novel tracer for patients with ductal carcinoma in situ to avoid unnecessary sentinel lymph node biopsy.

NICE Accredits Endomag’s Magtrace® Lymphatic Tracer for Staging Breast Cancer

Retrieved on: 
Wednesday, August 18, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Sentinel, NHS England, Union, Lymphatic system, Biopsy, Five Year Forward View, Government, University, National Institute for Health and Care Excellence, Cancer, Endomag, Lymph node, Kate Williams, Neoplasm, Science, Physician, European Union, Systematic review, Research, Accreditation, NICE, UCL, Lymph, Heart, Sentinel lymph node, Allergy, Hospital, Health, Multimedia, England, Methylene blue, Magnetism, Meta-analysis, NHS, Risk, Radionuclide, PLOS One, Patient, CEO, North Manchester, North Manchester General Hospital, Breast cancer, Woman, National Institute, Technology, University College London, Medical imaging, Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology

Endomags lymphatic tracer, Magtrace, has received an accreditation from the National Institute for Health and Care Excellence (NICE) for locating sentinel lymph nodes.

Key Points: 
  • Endomags lymphatic tracer, Magtrace, has received an accreditation from the National Institute for Health and Care Excellence (NICE) for locating sentinel lymph nodes.
  • To determine if breast cancer has spread, doctors analyse the sentinel, or nearest, lymph nodes to the tumour to see if they contain cancer cells.
  • Unlike technetium-99m, the Magtrace lymphatic tracer is manufactured in the UK and requires no nuclear facilities to be stored or used.
  • Endomag welcomes NICEs accreditation of the Magtrace lymphatic tracer and will continue to work to support access and improve standards of care for all breast cancer patients.

Endomag Secures £15 Million ($20 Million) in Series D Funding

Retrieved on: 
Monday, November 30, 2020
Oncology, Health, Medical devices, Surgery, Research, Science, Biotechnology, Endomag

Endomag, a breast cancer market leader and one of the UKs fastest growing private technology businesses1, has secured 15m (~$20m) in Series D funding.

Key Points: 
  • Endomag, a breast cancer market leader and one of the UKs fastest growing private technology businesses1, has secured 15m (~$20m) in Series D funding.
  • Draper Esprit led this funding round, the largest in the Companys history, which was supported by existing investors Sussex Place Ventures among others.
  • This investment follows on from Draper Esprits initial lead in Endomags 2018 Series C round, bringing the Companys total funding to over 32 million ($43 million).
  • 6 Endomag Website - Endomags #MagTeam100 Challenge raises nearly 25,000 for vital breast cancer research.

New View Surgical, Inc. Closes Series A Round of Financing

Retrieved on: 
Monday, June 17, 2019
Surgery, Health, Hospitals, Medical devices, Surgery, Medical technology, Robot-assisted surgery, Health, Medicine, Endomag

New View Surgical, Inc., an emerging medical device company developing proprietary imaging and access technologies for minimally invasive surgery, announced that it closed its Series A Financing Round at $2.5 million.

Key Points: 
  • New View Surgical, Inc., an emerging medical device company developing proprietary imaging and access technologies for minimally invasive surgery, announced that it closed its Series A Financing Round at $2.5 million.
  • The financing was over-subscribed due to investor demand.
  • New View Surgical will deploy the financing to complete the development of its VisionPort System, expand the companys intellectual property portfolio and submit a 510(k) U.S. Food and Drug Administration (FDA) filing.
  • New View Surgical is an emerging medical device company focused on the development and commercialization of the VisionPort System, a novel surgical imaging and access system for minimally invasive surgery.

Breast Lesion Localization Methods Market Worth $598 Million by 2024 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, May 16, 2019
Medicine, Medical specialties, Clinical medicine, Breast cancer, Hereditary cancers, Lymphology, Oncology, Sentinel lymph node, Endomag, Lymph node

By analyte type, the Breast Lesion Localization Methods Market is segmented into tumor identification and sentinel lymph node identification.

Key Points: 
  • By analyte type, the Breast Lesion Localization Methods Market is segmented into tumor identification and sentinel lymph node identification.
  • The sentinel lymph node identification segment dominated the Breast Lesion Localization Methods Market in 2018.
  • In 2018, the Asia Pacific held the largest share of the Breast Lesion Localization Methods Market, in terms of volume.
  • The prominent players in the Breast Lesion Localization Methods Market are Cianna Medical (US), Endomagnetics Ltd. (UK), and Cook Medical (US), C.R.

Breast Lesion Localization Methods Market Worth $598 Million by 2024 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, May 16, 2019
Medicine, Medical specialties, Clinical medicine, Breast cancer, Hereditary cancers, Lymphology, Oncology, Sentinel lymph node, Endomag, Lymph node

By analyte type, the Breast Lesion Localization Methods Market is segmented into tumor identification and sentinel lymph node identification.

Key Points: 
  • By analyte type, the Breast Lesion Localization Methods Market is segmented into tumor identification and sentinel lymph node identification.
  • The sentinel lymph node identification segment dominated the Breast Lesion Localization Methods Market in 2018.
  • In 2018, the Asia Pacific held the largest share of the Breast Lesion Localization Methods Market, in terms of volume.
  • The prominent players in the Breast Lesion Localization Methods Market are Cianna Medical (US), Endomagnetics Ltd. (UK), and Cook Medical (US), C.R.